Additional file 5 of Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study

  • Makito Miyake (Creator)
  • Kota Iida (Creator)
  • Nobutaka Nishimura (Creator)
  • Tatsuki Miyamoto (Creator)
  • Kiyohide Fujimoto (Contributor)
  • Ryotaro Tomida (Creator)
  • Kazumasa Matsumoto (Creator)
  • Kazuyuki Numakura (Creator)
  • Junichi Inokuchi (Creator)
  • Shuichi Morizane (Creator)
  • Takahiro Yoneyama (Creator)
  • Yoshiaki Matsumura (Creator)
  • Takashige Abe (Contributor)
  • Takeshi Yamada (Creator)
  • Naoki Terada (Creator)
  • Shuya Hirao (Contributor)
  • Motohide Uemura (Contributor)
  • Yuto Matsushita (Contributor)
  • Rikiya Taoka (Creator)
  • Takashi Kobayashi (Creator)
  • Takahiro Kojima (Creator)
  • Yoshiyuki Matsui (Creator)
  • Hiroshi Kitamura (Creator)
  • Hiroyuki Nishiyama (Creator)
  • Masaharu Inoue (Creator)

Dataset

Description

Additional file 5: Fig. S2. Landmark analysis of recurrence among patients treated with non-maintenance induction BCG (iBCG) or iBCG plus maintenance BCG (mBCG) at 24 months. Landmark RFS at 6, 12, and 18 months among patients treated with non-maintenance iBCG or iBCG plus mBCG are plotted and compared between matched groups A and B (left panel) and between matched groups B and C (right panel). The P values, hazard ratios (HRs), and 95% confidence intervals (CIs) are shown in the figures.
Date made available2021
Publisherfigshare

Access Dataset

Cite this